TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04329728: The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Sponsor: AVM Biotechnology Inc · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 144 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,241,680

Rescue Site Savings

+$818,380

Unlock Full NCT04329728 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04329728 Rescue Dossier →